Jacob Asset Management of New York’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Jacob Asset Management of New York’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$13.6K	Hold	15,655	–	–	0.02%	66
2023 Q2	$29K	Hold	15,655	–	–	0.03%	66
2023 Q1	$57.9K	Hold	15,655	–	–	0.07%	63
2022 Q4	$59.6K	Sell	15,655 -7,871	-33%	-$40.4K	0.07%	66
2022 Q3	$186K	Hold	23,526	–	–	0.2%	59
2022 Q2	$494K	Buy	23,526 +2,205	+10%	+$51.7K	0.5%	44
2022 Q1	$802K	Hold	21,321	–	–	0.49%	42
2021 Q4	$1.2M	Buy	21,321 +946	+5%	+$63.5K	0.53%	44
2021 Q3	$1.47M	Buy	20,375 +3,100	+18%	+$237K	0.53%	46
2021 Q2	$1.66M	Buy	17,275 +5,500	+47%	+$608K	0.55%	48
2021 Q1	$1.74M	Buy	11,775 +6,600	+128%	+$1.2M	0.67%	41
2020 Q4	$723K	Buy	+5,175	New	+$839K	0.55%	41

Other funds holding NBSE

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $78.9M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jacob Asset Management of New York's NBSE Position: Q3 2023 in Review

Jacob Asset Management of New York held its NeuBase Therapeutics, Inc. Common Stock (NBSE) position steady in Q3 2023 at 15,655 shares worth $13.6K. The position accounts for 0.02% of the portfolio, ranked #66.

Jacob Asset Management of New York first reported a position in NBSE in Q4 2020 and has held it in 12 quarters since. The position peaked at $1.74M in Q1 2021. 21 funds tracked by Wall St. Rank hold NBSE as of Q3 2023.

Jacob Asset Management of New York held 15,655 shares of NeuBase Therapeutics, Inc. Common Stock worth $13.6K as of Q3 2023.
Jacob Asset Management of New York left its NeuBase Therapeutics, Inc. Common Stock share count unchanged in Q3 2023.
NeuBase Therapeutics, Inc. Common Stock made up 0.02% of Jacob Asset Management of New York's portfolio in Q3 2023, its #66 holding.
Jacob Asset Management of New York first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2020 and has held it in 12 quarters since.
Jacob Asset Management of New York's NeuBase Therapeutics, Inc. Common Stock position peaked at $1.74M in Q1 2021.
21 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Jacob Asset Management of New York's 13F filing for Q3 2023, filed 1 Nov 2023.